Silexion Advances SIL204 into Phase 2/3 Trial for Pancreatic Cancer
Event summary
- Silexion Therapeutics initiated its Phase 2/3 clinical trial of SIL204 at Tel Aviv Sourasky Medical Center on July 29, 2026.
- Patient screening is expected to commence in the coming weeks, with first patient dosing anticipated to follow.
- Additional Israeli and German trial sites are progressing through activation and are expected to join the Phase 2/3 program in the coming months.
The big picture
Silexion's transition from regulatory preparation to active clinical execution marks a critical phase in the development of its lead siRNA product candidate, SIL204. The trial's focus on locally advanced pancreatic cancer, a highly lethal malignancy with limited treatment options, underscores the strategic importance of this milestone. KRAS mutations are prevalent in multiple high-value cancer indications, positioning Silexion to potentially expand into colorectal and lung cancers if SIL204 proves effective.
What we're watching
- Execution Risk
- How Silexion will manage the pace of patient screening and dosing across multiple sites.
- Regulatory Dynamics
- Whether additional EU member states, the United States, and other international jurisdictions will approve the trial in a timely manner.
- Clinical Efficacy
- The potential therapeutic benefits of SIL204 across KRAS-driven cancers beyond pancreatic cancer.
Related topics